bioMerieux (OTCMKTS:BMXMF) Hits New 12-Month Low – What’s Next?

bioMerieux (OTCMKTS:BMXMF)’s share price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $110.62 and last traded at $110.62, with a volume of 1 shares traded. The stock had previously closed at $111.10.

Wall Street Analyst Weigh In

Separately, BNP Paribas Exane downgraded shares of bioMerieux to a “neutral” rating in a report on Wednesday, January 28th. Two research analysts have rated the stock with a Hold rating, According to MarketBeat, the company currently has a consensus rating of “Hold”.

bioMerieux Stock Performance

The company has a 50-day simple moving average of $121.78 and a two-hundred day simple moving average of $129.14. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.27 and a quick ratio of 1.30.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.